ScholarLens Back to search
2019•Unpublished venueOpen access

A Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): IMvigor130

Jóse Ángel Arranz Arija, Maria De Santis

Open full text 4 citations

Abstract

Introduction and Objectives: First-line (1L) treatment (tx) for mUC includes cisplatin (cis)- or carboplatin (carbo)-based chemotherapy or checkpoint inhibitors, depending on patient (pt)- and tumour-specific factors. IMvigor130 is a Phase 3, global, randomised, study of atezo (anti–PD-L1) alone or +PBC vs placebo+PBC in untreated mUC. Materials and Methods: 1213 PBC-eligible mUC

About this research paper

What this paper is about

Introduction and Objectives: First-line (1L) treatment (tx) for mUC includes cisplatin (cis)- or carboplatin (carbo)-based chemotherapy or checkpoint inhibitors, depending on patient (pt)- and tumour-specific factors. IMvigor130 is a Phase 3, global, randomised, study of atezo (anti–PD-L1) alone or +PBC vs placebo+PBC in untreated mUC. Materials and Methods: 1213 PBC-eligible mUC

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Introduction and Objectives: First-line (1L) treatment (tx) for mUC includes cisplatin (cis)- or carboplatin (carbo)-based chemotherapy or checkpoint inhibitors, depending on patient (pt)- and tumour-specific factors. IMvigor130 is a Phase 3, global, randomised, study of atezo (anti–PD-L1) alone or +PBC vs placebo+PBC in untreated mUC. Materials and Methods: 1213 PBC-eligible mUC

Key concepts: Atezolizumab, Metastatic Urothelial Carcinoma, Medicine, Oncology, Placebo, Chemotherapy, Internal medicine, Urothelial carcinoma

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
A Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): IMvigor130 — Research Paper | ScholarLens